{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:15:16Z","timestamp":1787004916931,"version":"build-2736575974"},"reference-count":59,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients at extremes of body weight are underrepresented in randomized controlled trials of direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment remains a topic of debate.<\/jats:p>\n                  <jats:p>The aim of this narrative review is to summarize the evidence on the pharmacokinetic and pharmacodynamic profile of DOACs for treating patients at extremes of body weight in venous thromboembolism (VTE) and in the prevention of cardioembolic stroke in nonvalvular atrial fibrillation (NVAF). A literature search was conducted in the main bibliographic databases, and the most relevant reviews and original articles on the topic were selected.<\/jats:p>\n                  <jats:p>Although data in these patient groups are limited, apixaban and rivaroxaban show a favorable pharmacokinetic and pharmacodynamic profile in obese VTE treatment and NVAF patients and, in the case of apixaban, also in underweight patients. In particular, these drugs demonstrated comparable efficacy and safety to standard therapy. Very few data were available for dabigatran and edoxaban; the latter drug was safer at a lower dose, mainly in underweight patients.<\/jats:p>\n                  <jats:p>Our findings are in line with the last International Society of Haemostasis and Thrombosis position paper and European Heart Rhythm Association 2021 practical guide, suggesting the use of apixaban and rivaroxaban in morbidly obese patients (&gt;120\u2009kg or body mass index \u226540\u2009kg\/m2) and the reduced dosage of edoxaban in low-weight patients. Future studies should focus on large populations of patients at extremes of body weights to acquire more clinical and pharmacokinetic evidence on all available DOACs, especially those currently less investigated.<\/jats:p>","DOI":"10.1055\/s-0043-1776989","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T18:57:35Z","timestamp":1704740255000},"page":"e31-e41","source":"Crossref","is-referenced-by-count":14,"title":["Direct-Acting Oral Anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications"],"prefix":"10.1055","volume":"08","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3934-3775","authenticated-orcid":false,"given":"Rosa","family":"Talerico","sequence":"additional","affiliation":[{"name":"Section of Internal Medicine and Thromboembolic Diseases, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"},{"name":"IRCCS San Raffaele, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5224-2931","authenticated-orcid":false,"given":"Roberto","family":"Pola","sequence":"additional","affiliation":[{"name":"Section of Internal Medicine and Thromboembolic Diseases, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9961-0754","authenticated-orcid":false,"given":"Frederikus Albertus","family":"Klok","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2014Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno Volkert","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2014Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"},{"issue":"19","key":"ref2","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"T L Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"C T January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"T van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"J Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review","volume":"2","author":"J W Eikelboom","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/europace\/euz361","article-title":"Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis","volume":"22","author":"A H Malik","year":"2020","journal-title":"Europace"},{"issue":"25","key":"ref10","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Z J Ward","year":"2019","journal-title":"N Engl J Med"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"W Ageno","year":"2008","journal-title":"Circulation"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ahj.2007.10.004","article-title":"Atrial fibrillation and obesity\u2013results of a meta-analysis","volume":"155","author":"N Wanahita","year":"2008","journal-title":"Am Heart J"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.2007.06780.x","article-title":"Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations","volume":"139","author":"E R Pomp","year":"2007","journal-title":"Br J Haematol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"j1065","DOI":"10.1136\/bmj.j1065","article-title":"Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study","volume":"356","author":"M A Rodger","year":"2017","journal-title":"BMJ"},{"issue":"13","key":"ref16","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"A Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"J Steffel","year":"2021","journal-title":"Europace"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"K A Martin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1055\/a-1588-9155","article-title":"Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis","volume":"122","author":"T-F Wang","year":"2022","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10557-020-07122-6","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation and (morbid) obesity or low body weight: a systematic review and meta-analysis","volume":"36","author":"M Grymonprez","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/ajhp\/zxaa059","article-title":"Direct-acting oral anticoagulant use at extremes of body weight: literature review and recommendations","volume":"77","author":"K Covert","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/07853890.2014.982064","article-title":"Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials","volume":"47","author":"M ND Di Minno","year":"2015","journal-title":"Ann Med"},{"issue":"07","key":"ref23","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/jth.13701","article-title":"Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis","volume":"15","author":"K Boonyawat","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref25","first-page":"739","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"M Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.thromres.2016.09.010","article-title":"Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience","volume":"147","author":"D Arachchillage","year":"2016","journal-title":"Thromb Res"},{"issue":"26","key":"ref27","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"ref28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"H R B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"issue":"09","key":"ref29","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/jth.13051","article-title":"Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists","volume":"13","author":"E S Eerenberg","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.thromres.2021.10.009","article-title":"Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: drug levels and clinical outcomes","volume":"208","author":"A Ballerie","year":"2021","journal-title":"Thromb Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.thromres.2020.10.021","article-title":"UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: results from the FIRST registry","volume":"197","author":"V Speed","year":"2021","journal-title":"Thromb Res"},{"issue":"13","key":"ref32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"J I Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"D Kubitza","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"09","key":"ref34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1007\/s12325-021-01716-8","article-title":"Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY","volume":"38","author":"A T Cohen","year":"2021","journal-title":"Adv Ther"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/jcm10020200","article-title":"Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity","volume":"10","author":"A Cohen","year":"2021","journal-title":"J Clin Med"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/10600280221077158","article-title":"Observed Apixaban Anti-Xa Levels in obese patients","volume":"56","author":"W Harkness","year":"2022","journal-title":"Annals of Pharmacotherapy"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"V V Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"ref40","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"H R B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"ref41","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"S Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"07","key":"ref42","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"S Schulman","year":"2014","journal-title":"Circulation"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"S Schulman","year":"2013","journal-title":"N Engl J Med"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/0897190019854578","article-title":"Investigation of direct-acting oral anticoagulants and the incidence of venous thromboembolism in patients weighing \u2265120\u2009kg compared to patients weighing <120\u2009kg","volume":"34","author":"K G Aloi","year":"2021","journal-title":"J Pharm Pract"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"F A Klok","year":"2016","journal-title":"Eur Respir J"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1160\/TH16-10-0810","article-title":"External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism","volume":"117","author":"F A Klok","year":"2017","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref47","first-page":"747","article-title":"Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial","volume":"116","author":"P Verhamme","year":"2016","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.amjcard.2017.03.028","article-title":"Relation of risk of stroke in patients with atrial fibrillation to body mass index (from patients treated with rivaroxaban and warfarin in the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation trial)","volume":"119","author":"S R Balla","year":"2017","journal-title":"Am J Cardiol"},{"issue":"07","key":"ref49","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/03007995.2020.1762554","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data","volume":"36","author":"O S Costa","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/phar.2651","article-title":"Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI \u226550\u2009kg\/m2","volume":"42","author":"C P O'Kane","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"20","key":"ref51","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIRCULATIONAHA.118.037955","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight","volume":"139","author":"S H Hohnloser","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"ref52","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"P A Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"ref54","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"R P Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"ref55","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/eurheartj\/ehy861","article-title":"Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"G Boriani","year":"2019","journal-title":"Eur Heart J"},{"issue":"13","key":"ref56","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3390\/jcm10132879","article-title":"Impact of weight on clinical outcomes of edoxaban therapy in atrial fibrillation patients included in the ETNA-AF-Europe registry","volume":"10","author":"G Boriani","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"ref57","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2018.11.051","article-title":"Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight","volume":"73","author":"S-R Lee","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ijcard.2016.11.277","article-title":"Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran","volume":"228","author":"C-H Lee","year":"2017","journal-title":"Int J Cardiol"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1055\/s-0040-1716540","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial","volume":"121","author":"G Boriani","year":"2021","journal-title":"Thromb Haemost"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1776989.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T08:13:26Z","timestamp":1730794406000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1776989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":59,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1776989","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}